Skip to main content

Accessibility Tools

MYONEX EVENT “Inside Clinical Supplies”

Facility Open House, Hands-on Experiences, Conferences & Networking
November 5 • 9:30AM-5:30PM • Myonex Le Haillan [Bordeaux, France]

Case Study

Ensuring Reliable Supply for a Complex EU & UK Pivotal Rare Disease Gene Therapy Trial: The Genethon case

Trial Sponsor: Genethon  

Study: Randomized, double-blind pivotal trial of a microdystrophin gene therapy in Duchenne Muscular Dystrophy (DMD). 
Duration: 6 years (expected) 
Location: Sites in France, Belgium, Spain and United Kingdom 
Patients: 20-40 children with DMD 
Products: Investigational Medicinal product (IMP) GNT0004, a gene therapy product, Auxiliary Medicinal Products (AMPs) and infusion kits 

Challenge

Genethon is conducting a randomized, double-blind pivotal clinical trial evaluating GNT0004, a gene therapy developed for Duchenne Muscular Dystrophy, a rare pediatric disease. This two-year multicentric study targets 20 to 40 children across investigational sites in France, the United Kingdom, Spain and Belgium and relies on a complex clinical protocol. 

The pivotal phase involved the simultaneous management of multiple IMPs, AMPs and infusion kits, each with different regulatory statuses and temperature requirements ranging from ultra-low storage at -80°C (IMP) to refrigerated (AMPs) and +15/+25°C (infusion kits) conditions.  
The investigational gene therapy product, an Advanced Therapy Medicinal Product (ATMP) and Genetically Modified Organism (GMO) class I, required strict handling constraints and precise coordination to preserve trial integrity.  
In parallel, several commercial products had to be relabeled and sourced specifically for certain countries, including the UK.  
The study also required the assembly and distribution of highly complex infusion kits, incorporating up to 55 individual components that had to be coordinated, packaged and supplied with absolute precision. 

This complexity was further intensified by country-specific regulatory requirements, the need to combine EU QP release and UK QP oversight, and the obligation to secure product availability for first patient dosing without delay. Ensuring seamless execution across multiple sites, geographies and temperatures, while maintaining blinding, compliance and timelines, represented a major operational challenge for Genethon. 

The Myonex Solution

As part of a long-term partnership with Genethon, following the successful management of the previous Phase I/II/III study, Myonex took full operational ownership of the clinical supply execution for the pivotal trial across Europe and the United Kingdom, ensuring supply continuity, speed and control at this decisive milestone. 

At the core of this model, a dedicated Myonex Project Manager acted as Genethon’s single point of contact, orchestrating all workstreams (packaging, labeling, QP release, distribution and returns) across Myonex sites. A structured governance framework, including regular status meetings, shared supply forecasting, proactive risk management and clear escalation paths, ensured that every activity was planned, aligned and executed in the right sequence. 

Myonex managed the labeling and distribution of investigational and auxiliary medicinal products, as well as complex infusion kits, across multiple temperature ranges including ultra-cold handling at -80°C. Parallel blinded operations were implemented for products and matched placebo, supported by plausibility analyses to ensure visual and logistical consistency and to protect the integrity of the double-blind design. 

Labeling strategies were adapted to product use and administration settings, with English-only labeling for products administered on site and multilingual booklets for products taken at home.  

Distribution was organized through a dual-hub model, with Myonex Le Haillan supplying France, Spain and Belgium, and Myonex UK supplying UK sites across all required temperature conditions. Considering the high value of the investigational gene therapy product, Myonex also implemented a tightly controlled return and reallocation process under formal authorization from the French competent authority (ANSM). 

From a regulatory perspective, Myonex ensured full EU QP release through its Le Haillan site in France, certifying the end-to-end supply chain, while providing QP oversight for the UK via its Leicester site.  

Throughout the study, this project management backbone ensured close coordination with Genethon’s teams, including IRT-related execution support, to accelerate site readiness and secure reliable supply for patient dosing.

“A consistent and high-quality operational support! Our double-blind, pivotal gene therapy trial required packaging, labeling and distribution of multiple IMPs, AMPs and infusion kits at -80°C, 2-8°C and 15-25°C. Myonex met every deadline with precision. Myonex ensured QP release for Europe, and handled QP oversight for the UK. Their support enabled on-time dosing of our first patient and timely site readiness. A particularly strong and reliable partnership.”
– Genethon

 

Results

First patient dosed on time: All investigational products, auxiliary therapies and infusion kits were available as planned, enabling on-time site readiness and first patient dosing despite protocol complexity. 

Full control of a multi-product, multi-temperature supply chain: IMPs, AMPs and infusion kits were successfully managed across -80°C, +2/+8°C and +15/+25°C, without disruption to study timelines or site operations. 

Preserved double-blind integrity: Parallel IMP and placebo operations, supported by plausibility analyses, ensured consistent blinding across batches, sites and countries. 

Regulatory compliance secured across EU and UK: EU QP release and UK QP oversight were delivered seamlessly, supporting compliant trial conduct across multiple geographies and product typologies, including ATMPs. 

Controlled costs for high-value IMPs: A strict ANSM-approved return-and-reallocation process enabled recovery of unused IMP vials whenever appropriate, limiting waste while maintaining full traceability and quality oversight.

Conclusion

This pivotal rare disease gene therapy trial highlights Myonex’s ability to manage highly complex, multicentric clinical supply chains involving sensitive and high-value products such as ATMPs, blinded operations and multi-temperature distribution across Europe and the UK.  

By combining dedicated project management with close collaboration with the sponsor, operational ownership and regulatory expertise, Myonex enabled Genethon to progress confidently through a critical phase of clinical development, ensuring patients could be treated on time.